Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Chugai Logs Bumper Earnings in January-September on New Products, Exports to Roche
October 25, 2022
- Bayer Launches Xarelto Tablets 2.5 mg for PAD as Single-Channel Product
October 25, 2022
- LEO Pharma to Take Over Dovonex Distribution, Set Up Solo Sales Regime in Japan
October 25, 2022
- GSK Seeks Japan Approval of RSV Vaccine
October 24, 2022
- Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
- Approval by January Unlikely for SanBio’s Lead Cell Therapy as Production Review Stalls
October 21, 2022
- Sunovion to Divest US Market Rights of 2 Drugs to Lupin for US$75 Million
October 21, 2022
- Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
- Bayer to Halt Sale of PAH Med Ventavis in Japan over Nebulizer Supply Issue
October 20, 2022
- MSD Started Work to Develop Easier-to-Swallow Form of Lagevrio: Exec
October 20, 2022
- Sumitomo Aiming to Take the Lead in Developing Universal Flu Vaccines
October 19, 2022
- Chugai’s Integrated Drug Discovery Research Center Completed in Yokohama
October 19, 2022
- Kyowa Kirin Files Intas-Licensed Mitomycin for Cancer Use in Japan
October 19, 2022
- Bayer to Distribute Xarelto Tablets 2.5 mg via Single Wholesaler
October 18, 2022
- Fuji Pharma Files 1st Biosimilar Out of Alvotech Collaboration
October 18, 2022
- Takeda’s Dengue Vaccine Secures Positive Opinion in EU
October 18, 2022
- Mitsubishi Tanabe’s Neuromyelitis Optica Spectrum Disorder Med Approved in Taiwan
October 18, 2022
- Shionogi Eyes FY2024 Japan Filing of Regeneration-Inducing Medicine
October 17, 2022
- Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…